<SEC-DOCUMENT>0001075880-13-000027.txt : 20130403
<SEC-HEADER>0001075880-13-000027.hdr.sgml : 20130403
<ACCEPTANCE-DATETIME>20130402180256
ACCESSION NUMBER:		0001075880-13-000027
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130403
FILED AS OF DATE:		20130403
DATE AS OF CHANGE:		20130402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		13737126

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6kproforma.htm
<DESCRIPTION>CONVERTED BY EDGARWIZ
<TEXT>
<HTML>
<head><title>Converted by EDGARwiz</title> </head> <body style="MARGIN-TOP:0px; FONT-FAMILY:Times New Roman; COLOR:#000000; FONT-SIZE:10pt"> <div style=WIDTH:601px> <p style="LINE-HEIGHT:12pt; MARGIN:0px; PADDING-LEFT:56px" align=center><b>UNITED STATES </b></p> <p style="LINE-HEIGHT:12pt; MARGIN:0px; PADDING-LEFT:56px" align=center><b>SECURITIES AND EXCHANGE COMMISSION </b></p> <p style="LINE-HEIGHT:12pt; MARGIN:0px; PADDING-LEFT:56px" align=center><b>Washington, D.C. 20549 </b></p> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>&nbsp;</p> <p style="MARGIN-TOP:0px; PADDING-LEFT:56px; MARGIN-BOTTOM:16px; FONT-SIZE:14pt" align=center><b>Form 6-K </b></p> <p style="LINE-HEIGHT:14.4pt; MARGIN-TOP:0px; PADDING-LEFT:56px; MARGIN-BOTTOM:14px; FONT-SIZE:11.5pt" align=center><b>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 </b></p> <p style="LINE-HEIGHT:12pt; TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=left>For the month of April, 2013. </p> <p style="LINE-HEIGHT:12pt; TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>Commission File Number ________________ </p> <p style="LINE-HEIGHT:12pt; MARGIN:0px" align=center><br></p> <p style="LINE-HEIGHT:12pt; MARGIN:0px; PADDING-LEFT:56px; FONT-SIZE:20pt" align=center><b>Novogen Limited</b></p> <p style="LINE-HEIGHT:12pt; MARGIN:0px; PADDING-LEFT:56px" align=center>(Translation of registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s name into English) </p> <p style=MARGIN:0px align=justify><br></p> <p style="MARGIN:0px; PADDING-LEFT:56px; FONT-SIZE:12pt" align=center>1-7 Waterloo Road, Macquarie Park, NSW, Australia</p> <p style="LINE-HEIGHT:12pt; MARGIN-TOP:0px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px" align=center>(Address of principal executive office) </p> <p style="LINE-HEIGHT:13.55pt; TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px; PADDING-RIGHT:71px" align=left>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p> <table style="MARGIN-TOP:0px; FONT-SIZE:10pt" cellpadding=0 cellspacing=0> <tr style=FONT-SIZE:0px> <td width=585 /> </tr><tr> <td width=585 style=MARGIN-TOP:0px valign=top> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>&nbsp;Form 20-F<font style=FONT-FAMILY:Wingdings> </font><font style=FONT-FAMILY:Wingdings><font face=Wingdings>x</font>&nbsp;</font><font style="FONT-FAMILY:Wingdings 2">&nbsp;</font>Form 40-F<font style=FONT-FAMILY:Wingdings> </font><font face=Wingdings>o</font></p></td></tr></table> <p style="LINE-HEIGHT:13.55pt; TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px; PADDING-RIGHT:71px" align=justify><b>&nbsp;</b>&nbsp;</p> <p style="LINE-HEIGHT:12pt; MARGIN-TOP:0px; TEXT-INDENT:-56px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px" align=justify>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <font face=Wingdings>o</font></p> <p style="LINE-HEIGHT:12pt; MARGIN-TOP:0px; TEXT-INDENT:-56px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px" align=justify><b>Note</b>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </p> <p style="LINE-HEIGHT:12pt; MARGIN-TOP:0px; TEXT-INDENT:-56px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px" align=justify>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<font face=Wingdings>o</font></p> <p style="LINE-HEIGHT:12pt; MARGIN-TOP:0px; TEXT-INDENT:-56px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px" align=justify><b>Note</b>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>home country<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font>), or under the rules of the home country exchange on which the registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </p> <p style="LINE-HEIGHT:12pt; MARGIN-TOP:0px; TEXT-INDENT:-56px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px" align=justify>Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. &nbsp;Yes&nbsp;&nbsp;<font style="FONT-FAMILY:Wingdings 2"><font face=Wingdings>o</font>&nbsp;</font>No <font face=Wingdings>x</font></p> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>If <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>yes<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)</p> <p style="LINE-HEIGHT:12pt; MARGIN:0px" align=center><br></p> <p style="LINE-HEIGHT:12pt; MARGIN:0px; PADDING-LEFT:56px" align=center><b>SIGNATURES </b></p> <p style="LINE-HEIGHT:12pt; MARGIN-TOP:0px; TEXT-INDENT:-56px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px" align=justify><b>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf</b> by the undersigned, thereunto duly authorized. </p> <p style="LINE-HEIGHT:12pt; MARGIN-TOP:0px; TEXT-INDENT:-56px; PADDING-LEFT:56px; PADDING-RIGHT:20px; MARGIN-BOTTOM:13px" align=justify><b>Novogen Limited</b> (Registrant) </p> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>&nbsp;</p> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>(Signature) *</p> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>Andrew Bursill</p> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>&nbsp;</p> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>Date&nbsp;3 April&nbsp;2013</p> <p style=MARGIN:0px align=justify><br></p> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px; FONT-FAMILY:ClassGarmnd BT,Times New Roman; FONT-SIZE:9pt" align=justify>* Print the name and title under the signature of the signing officer.</p> <p style=MARGIN:0px align=justify><br><br></p></div></body>
<!-- EDGAR Validation Code: A209A7A8 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ovarianannouncement2.htm
<DESCRIPTION>CONVERTED BY EDGARWIZ
<TEXT>
<HTML>
<head><title>Converted by EDGARwiz</title> </head> <body style="MARGIN-TOP:0px; FONT-FAMILY:Times New Roman; COLOR:#000000; FONT-SIZE:10pt"> <div style=WIDTH:553px> <p style="MARGIN-TOP:0px; MARGIN-BOTTOM:16px" align=justify><img alt=[ovarianannouncement2001.jpg] src=ovarianannouncement2001.jpg align=middle></p> <p style="MARGIN:0px; FONT-SIZE:12pt"><b>ASX Release</b></p> <p style=MARGIN:0px><br></p> <p style="MARGIN:0px; FONT-SIZE:12pt"><b>3 April 2013</b></p> <p style=MARGIN:0px><br></p> <p style="MARGIN:0px; FONT-SIZE:12pt"><b>Potency of CS-6 against cancer stem cells confirmed in follow-up study.</b></p> <p style=MARGIN:0px><br></p> <p style="MARGIN:0px; FONT-SIZE:12pt">Novogen previously (18 February 2013) announced data from a sighting study that showed that the experimental anti-cancer drug, CS-6 was highly cytotoxic in the laboratory against ovarian cancer stem cells (OCSC). That study served as a guide to the merits of conducting more extensive studies.</p> <p style=MARGIN:0px><br></p> <p style="MARGIN:0px; FONT-SIZE:12pt">The follow-up study went on to examine the effect of CS-6 against a range of other OCSC cell lines, including cell lines virtually indestructible by both standard-of-care and experimental anti-cancer drugs. The study also looked at the effect of CS-6 on the differentiated daughter cells of these cancer stem cells, mirroring the situation in patients with ovarian cancer where the cancer responds to chemotherapy initially, but then recurs. Recurrence in that case being the result of the chemo-resistant cancer stem cells in the tumor surviving the chemotherapy to produce a new population of daughter cells with increased resistance to chemotherapy.</p> <p style=MARGIN:0px><br></p> <p style="MARGIN:0px; FONT-SIZE:12pt">Novogen Chief Scientific Officer, Dr Andrew Heaton, today said, <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>The cancer stem cell lines that were used in this follow-up study are extraordinarily difficult to kill. They are impervious to virtually all drugs. Drug levels required to kill these cells typically have been so high as to be impractical or would be so toxic as to destroy the rest of the body. The behavior of these cells is why late-stage ovarian cancer carries such a poor prognosis.<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font></p> <p style=MARGIN:0px><br></p> <p style="MARGIN:0px; FONT-SIZE:12pt"><font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>CS-6 proved to be highly cytotoxic against all cancer stem cell lines tested. But even more impressive was the sensitivity of the cancer stem cells to CS-6, with both the cancer stem cells and their daughter cells being wiped out at drug levels down to picomolar levels. Just as remarkably, the cytotoxic effects of CS-6 were evident as early as 4 hours.<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font></p> <p style=MARGIN:0px><br></p> <p style="MARGIN:0px; FONT-SIZE:12pt">Novogen CEO, Dr Graham Kelly, added, <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>These results are a key step in our goal of developing first-in-class drugs offering comprehensive anti-cancer therapy and bringing hope to cancer sufferers world-wide. For many common cancers, cancer stem cells are thought to be the reason why cancers recur after responding initially to treatment. Having the ability to knock out these progenitor cells holds the potential at most of being able to block the growth and establishment of cancers, and at least of being able to prevent or slow down cancer recurrence following anti-cancer therapy.<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font></p> <p style=MARGIN:0px><br></p> <p style="MARGIN:0px; FONT-SIZE:12pt"><font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>As usual, this is one small, but important, step in our goal with many more steps to go before we can declare success, and investors should be aware of the timelines and risks involved,<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> Kelly added.</p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style="MARGIN:0px; FONT-SIZE:12pt"><b>About Novogen</b></p> <p style="LINE-HEIGHT:15.75pt; MARGIN-TOP:0px; FONT-FAMILY:Cambria,Times New Roman; MARGIN-BOTTOM:30px; FONT-SIZE:12pt"><font style=BACKGROUND-COLOR:#ffffff>Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#145;</font></font><font style=BACKGROUND-COLOR:#ffffff>NRT</font><font style=BACKGROUND-COLOR:#ffffff><font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>) and NASDAQ (symbol <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#145;</font></font><font style=BACKGROUND-COLOR:#ffffff>NVGN</font><font style=BACKGROUND-COLOR:#ffffff><font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>). &nbsp;The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on comprehensive anti-cancer activity against both cancer cells and cancer stem cells. The Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s inaugural drug candidate is CS-6.</font></p> <p style="MARGIN:0px; FONT-SIZE:12pt"><b>About CS-6</b></p> <p style="LINE-HEIGHT:15.75pt; MARGIN-TOP:0px; FONT-FAMILY:Cambria,Times New Roman; MARGIN-BOTTOM:30px; FONT-SIZE:12pt"><font style=BACKGROUND-COLOR:#ffffff>CS-6 belongs to a new family of drugs known as </font><font style=BACKGROUND-COLOR:#ffffff><i>super-</i></font><font style=BACKGROUND-COLOR:#ffffff><i>benzopyrans</i></font><font style=BACKGROUND-COLOR:#ffffff> which Novogen has developed and which have a number of design features purposely built into them, viz. (i) ability to kill both cancer stem cells and their daughter cells, (ii) ability to cross the blood-brain barrier, and (iii) improved bio-availability.</font></p> <p style="LINE-HEIGHT:15.75pt; MARGIN-TOP:0px; FONT-FAMILY:Cambria,Times New Roman; MARGIN-BOTTOM:30px; FONT-SIZE:12pt"><font style=BACKGROUND-COLOR:#ffffff>CS-6 is being developed as a treatment of </font><font style=BACKGROUND-COLOR:#ffffff>glioblastoma</font><font style=BACKGROUND-COLOR:#ffffff> </font><font style=BACKGROUND-COLOR:#ffffff>multiforme</font><font style=BACKGROUND-COLOR:#ffffff>, the main form of primary brain cancer, and late-stage, chemo-refractory ovarian cancer.</font></p> <p style="MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman; FONT-SIZE:12pt"><b>About Cancer Stem Cells</b></p> <p style="MARGIN:0px; FONT-SIZE:12pt">Cancer stem cells (CSC) (or tumour-initiating cells) are believed to be a subpopulation of cells within many types of cancer that are responsible for driving the growth and spread of the cancer. CSC typically are resistant to radiotherapy and chemotherapy and are thought to be responsible for cancer recurrence following therapy. Targeting CSC is a new direction in oncology drug development as a means of preventing cancer recurrence.</p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style="MARGIN:0px; FONT-SIZE:12pt"><b>Further information</b></p> <p style="LINE-HEIGHT:15.75pt; MARGIN-TOP:0px; FONT-FAMILY:Cambria,Times New Roman; MARGIN-BOTTOM:30px; FONT-SIZE:12pt"><font style=BACKGROUND-COLOR:#ffffff>Contact Dr Graham Kelly, Chief Executive Officer.</font></p> <p style="MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman; FONT-SIZE:12pt">T: &nbsp;(61 2) 9878 0088</p> <p style="MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman; FONT-SIZE:12pt">M: (61) 0459 200 095</p> <p style="MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman; FONT-SIZE:12pt">E: <u>Graham.Kelly@novogen.com</u></p> <p style=MARGIN:0px><br></p> <p style="LINE-HEIGHT:15.75pt; MARGIN-TOP:0px; FONT-FAMILY:Cambria,Times New Roman; MARGIN-BOTTOM:30px; FONT-SIZE:12pt"><font style=BACKGROUND-COLOR:#ffffff>Further information is available on the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s web site, </font><font style=BACKGROUND-COLOR:#ffffff><u>www.novogen.com</u></font></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style="LINE-HEIGHT:17.4pt; MARGIN-TOP:0px; MARGIN-BOTTOM:22px"><br></p> <p style="LINE-HEIGHT:17.4pt; MARGIN-TOP:0px; MARGIN-BOTTOM:22px"><br></p></div></body>
<!-- EDGAR Validation Code: CAE04F84 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ovarianannouncement2001.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 ovarianannouncement2001.jpg
M_]C_X``02D9)1@`!`0```0`!``#__@`[0U)%051/4CH@9V0M:G!E9R!V,2XP
M("AU<VEN9R!)2D<@2E!%1R!V-C(I+"!Q=6%L:71Y(#T@.3`*_]L`0P`#`@(#
M`@(#`P,#!`,#!`4(!04$!`4*!P<&"`P*#`P+"@L+#0X2$`T.$0X+"Q`6$!$3
M%!45%0P/%Q@6%!@2%!44_]L`0P$#!`0%!`4)!04)%`T+#104%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\``$0@`
M@`/H`P$B``(1`0,1`?_$`!\```$%`0$!`0$!```````````!`@,$!08'"`D*
M"__$`+40``(!`P,"!`,%!00$```!?0$"`P`$$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$`!\!``,!`0$!`0$!`0$````````!`@,$!08'"`D*"__$`+41``(!
M`@0$`P0'!00$``$"=P`!`@,1!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:``P#
M`0`"$0,1`#\`_5.BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**C
M9]HS@GZ=:CBE\V-&92I8=#U''-'F!8HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*0]*6
MD)XH`BDPJD]J\]^!WCQ?B'\,-"U9GWWGEM:7@`P5N(7:*4'_`('&Y]P1ZC/H
M$J[D8#@D5^<G[+G[0:?!/X]>./A_XCN5M_#FJZ_="":8[5L[WSF3#$_=5U51
M@\+L')Y)UIPYU9;GF8G%K#5H*7PRT/TAW>U.J!9=P''7KR.*FR*R\CTM]1:*
M**!A1110`444F:`%HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`&\
M$4&D)P*S-7UVRT*Q>[U"Z@LK=&"M+<2A$&3@98]*72X)-M16[-2EZBL'0_&6
MC>)7D72M3L]2,0#2"TN%DV`],[2?>MLO@'`_"E=6N5*$H.TE9CLD4O6HB^!D
MXSCN>E8VD>,]$\17$D&E:M8ZC-$NYX[:X21D7ID@'(YXIW5["2<E=(WZ*A,I
M&?EX`I'F`Y/W?7-,2U)6_*D/*&N,\3?%WP=X/G:#6?$NE:;<JNXPW-XB.!Z[
M2<@>^*H:+\?/A]XBF$&F^+](NIFX5$O$W$^@!(K-U()ZLZHX3$2CSQIRMWL[
M'>M\ZLN`<\<]*_&+]K#PT?#G[1OQ"LI-SK-JCWH,@(!$X$V/I\Y'TK]EEN/,
M4%.=V,$$'_/^>E?F%_P4D\(OH7QXL-<",L&NZ5&X8GY3-"QC<>Y"^5S_`+7M
MSZ&$:YSXSB"C)X536\6>C?L3_MDLCZ;\//'E\2PQ;Z/K-RV=^!@6\K'^(9`5
MSU'!]:^_HY@Z@@'D9QW%?@49,Y8]>[$\G!]>WU'-?IW^PI^T_)\4]$;P7XFN
M@_BW1X08;B0_-J%LN%WM_P!-5RH<#.<JWJ!KBJ'VHG%DN:.=L/5>O0^PJ0U'
MOQC(P3ZGFG;CZ5YQ]L+CC)ZT8KGV\:Z(FL+I+:K9+J;':+,W*B8L1N`V9SG'
M.*V1.<G*@`#D@Y`/I0M=ARA*/Q*W4G^M(1@]JP/$?CK0_"-OYVMZK9Z7%_ST
MNIUC4GTYKD8?VD_AE<SF"/QMHS2`XP;M0/SZ5#G&+LV=$,+B*L>:%.37DF>G
M#Z4N/6LS3-:L]:M4N;&YAN[>0966&0.K#M@C(-75EW`<`'H1W%6<[BXNTE8G
MHIA?"YQFHI+E8U))7CJ,T"W)CQ0.:\_USXZ^`?#5PUOJ7BW1[2X0D-"]XF]?
MJN:32OCW\/M;F6&R\8Z-<2,,JJWB9/ZUG[6'<Z_J>)Y>?V<K=[,]#HJG;WD=
MW&KPNLB,,JZG((^O^%233K#$TDA$:*,LS-@`>N:JZ:N<C33L3X-&#7'#XL^#
M^<^*-&49P"=0B`/YMU]J>/BOX-8<>*=&SZ&_B_\`BJ7/'N;>PJ_R/[CK?PH.
M,5SVB^.-!\1SR0:5K%AJ4T:AW2TNDE95)QDA2<"M/4=5M=*LI;R]N(;.UB&Z
M2:=PB(/4L>`/>JOU,W"47RM69>HZ5@:+XWT/Q#.T&EZK8ZC,@W/':W*2,J^I
M`-;@E!R`,TDU)702A*#M)68^EZBHRWRY/&*P=+\;:%K6I2Z?8:O87EY%G?;P
M72/(N#@Y4'/!XHNE9=Q*,I7:6B.CHI`<TM4(****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"D/W:6D/2@",\Y]\U\\?MUH#^SKKF0&S+;<
M$9S^]7_'O7T0>#BOGK]NL8_9VUWG'[ZW_P#1R5SUOX4CU\HL\PHI_P`R/AOX
M)^/=7^`'BSP]XT6$_P#"/:JTUO<QQ#(N(4?;,`!_RT0J&QZ=^>/U4T+7+3Q%
MI%GJ>GRI<6EW$LT4T;`JR,H*D'T/%?%7P7^"]M\:_P!CV;2PL<6KVNH7MSIM
MR1@QW`E<CGL&'R'M@]#C!L?L+?&6ZT?4[SX6>),VEU;R2G38KCAD96/G6W/]
MTY91Z;NV*\["SE2Y8R>C/L<^I0S/VM:FOWE)VE;K'H_D?;-Z2+>1>VSJ:^!?
M^"=\:)\4_&TB@!FL06.U1G-PWMG]37WO<L9(G'`&WD@]:^"_^"=Y(^*/C4CM
M8J?_`"8:NVMK4@K[GSV6QME^+;5](OTU/OUR`.<8SZU\*_M0?M5Z_KOBN3X>
M_#N2:.0S_8I[ZQ!:>YN"<&"#T'4%O4$<8S7U)^T#XXG^'OP<\6:];-LO+2Q?
MR&_Z:D;4/X,0:^4/^">GPPM]6UK7/&U\@GDL";"S=QG]ZX#RRY/\1RH_[Z.>
M<#/$3<I*BNITY-AZ-'#5<RQ,>90LHK^\]C6^&/\`P3ZAU&V34_B#K5W)>S?O
M6L;!Q\C'G]Y,X,COSVV@'UKH/'/_``3N\+7]@\OA/6;_`$?447,4=XPN868>
MI/SJ2>ZMQUP:^OPAQC/7VXI=FU2<CIZ5HL)170X)\09A*IS\[7DK6^X_.+X5
M?'CQK^R]X^/@OQY]HO-!A=8YK>1S*ULC=)[=VP7BXZ<<9X!X/K7_``40\!Q_
M$#X%Z9XQTSR[Q]`G2\%Q&05>SG`21E/<9,3Y]%-;?[>_PTM/$/PN3Q7'"#J?
MA^8-YJ_>>WD8)(A]@6##T*@T_P#8NU:#XI?LX7OA77=M];63SZ-/%(<[[9T!
M5?8!7*@<X"BIPU2>'Q'LWMT.G/\`"4<YRI9A2CRR;Y9);-VT?S/RM*')SP1U
M'I[?UKH/`?C;5?AQXPTGQ/HDIAU/2YUGAR?E<`\HWJ&4LI]0S>Q&U\9?A=J'
MP7^).M>$M2!,EE+OM[@J0MS;N#Y4@^HRN.<%&&3@$\)GL1FOLKJK`_FJ4:F%
MJM;.)^Z'PU\<:=\1_`^A^)M*;?9:K:I=1C()3<,LI]"K94CL01VK8U[6(-"T
M>]O[J01P6L#S2.W1549)_2OC+_@F3\1VU?P+XC\%W,FZ31KI;VT!8EOL\XRR
MX[`2I(V?63MCGTS]NSXBCP7\%KK3(IS#>Z_(+!"APRQ8WS-_W[5Q]2*^:Q+5
M'F;V1^U9&GFDJ,([RM?]3Q']CK1)/C%^T)XJ^)VHVRM':2//"[+G$LV5B`SW
M6$=N[#I7NO[5_P"TPOP4TF#2='\FX\6ZC&3`)>4M8QD-.X[X[`XS@\\8.C^Q
MW\/?^%>_!#2'NH?)U+5B^IW:D=&D^XI_W8U1>W0\#.*^1-%L1^TS^V)=#46:
MZT:749973JIL;8E43V#;%!]3(WK7DMSA2C%/WI'Z)3IX?'YE6KUHWHT%MWMH
ME\V;_P`)?V5_%O[1VWQGX^\07UK87G[V!YU$EY.A)Y56RD4?]WY22.<"O;=2
M_P"">GP[GTOR+6^UFSNU`Q<?:Q*,^\;J4`]E45]006<=K'&D*)%$G`1%PHXP
M,#MZ59$>"2#75#"PBO?U9X6(X@QM2IS49<D5M%=%V/S0\1^%?B7^Q+XJL[S3
M-3>]\,W,I6-XU;[)<G.3%-$2?+D*@@%3@GT-?=?P3^+>E?&;P'9>(]-_<L_R
M75J6RUM.!\\9X&0.H.!D$'`S6E\4/A]IWQ*\#:SX=U-1+:WT#("P&8WQ\C+[
MJV&!ZY'6OB7]@GQ)J/A#XQ:]X,O9"/MD$IFB)R!<6S;"P]"5)!'^RM8I.A54
M6_=EL>I4<,\RZ=>44JU*S;6TEY^9][ZYKUEX<TB]U/4[A+/3[*)Y[FXF.$BC
M499C[8K\_P#QC\8_B-^UUX\F\*>!&GT;PTI)\L,828<X\ZYD'S*"#D(OL.>2
M/7?^"A?CR;0/A[H_ARUE,3:S=E[@@X)AA`8K]"Q4D^BXP<\=M^QE\*[3X?\`
MP9T6_6)!JNN1)J-U,1EG5U)B7/4!48''JS>M.JY5JWLEHEJS'`PHY9E[S*K'
MFJ3?+!/96W9YWX4_X)S>&K6VB?Q)XDU/4+P_,Z6(C@AW>JY#/GWW9/M4GBC_
M`()Q>#[R*1M&\0:MILF#L2<0W,0/KADW9]PP-?8!A&!@XQW[_2G%<CMGU(K?
MZK2_E/+_`-8,RYN;VK]-+?<>&?LN_!37O@KX7U/3=?UHZQ+/>%[=(II&@@A"
MX7RT?)0L2Q(!(`V@'CGU;QL%;P=K*]OL<O7_`'#6X%&0=V2.*Q?'&$\(:T><
M?8YNG^X:U<5"#2/,]M+$XI59[MK\S\UOV3OV;-!^/[^)1JVHWNE-I?D&+^SA
M"-_F&7=NWHV?N?K7T+_P[;\$8)/B?7_RM,?^B*Y/_@FW/':3>//,=8]WV(+O
M(7)!GR/?J*^X9+^V5?\`71$=_G'%<-"E1E33:_$^QSK-,PP^-G3HS:6EM%V7
MD>(_`?\`9/\`#_P&\0ZAK.DZOJ6HSWUJMI(MZ(=H56W`C9&ISGUS6O\`M8)_
MQCOX['WP--<X*YSR/SZ]*];BE66,/&0Z$<%3D&O*?VL2!^SMX\.<$Z:_3KU%
M=DHQITVH*VA\OAZ]7$8ZE5K.\N9?FNA^<7PI\3:Y\%M?\/\`Q#TNV+Z9)>S6
M$BQ\"Z5`IFB;`X8JP9#SGTXK]6/!?BK3?'/AO3M=TBX6[L+^!)H94/WE/?Z]
M>.Q!KXY_9<^%-A\8_P!E?Q/X=O!Y<DVL3R6MRJY:VN%2)DD7T^;MZ'&>]4_V
M,OBOJ'PQ\>:C\)?%1-KOO)%LUD;Y8+L9WQ+Z)(H#H/7=C.:\[#3E0Y8O:7YG
MVV>THYI[:<$O:T79VZQ[_(^\)EW1L!P<9YK\Z_V.;=/^&KO$A5%!7^TF!"@'
M'VIN,XYZ]Z_1%IE:)F/`VYYK\\_V-SC]J[Q-CTU0?^39KHQ',ZE-)]3Q,CBG
M@L:WTBK?>?HJHP*=31]RG5Z)\<%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!112'@$T`,?K7SU^W5_R;MKG_`%UM_P#T:M?0IZC/>OGG
M]NEL_L[ZX/\`IM;_`/HY:YZ_\*1[&3?\C"BO[R*7[`RY^`<7&0=2O!]?WIKR
M?]MWX0WGA#Q+8_%3PONL[A)XS?RP`DPSJ0(I\>APJOZ@#WSZS^P)S\`H1G!_
MM.\_]&M7O/B/PW8^*M"O])U*W2ZLKR![>:)QD,C#!!_,UA"FJE"*/7K8^6`S
MFK5WCS--=TSS_P"`GQAM?C/\,K77(!Y%]&IM[^U;[UO<*,.GN.0P/&0P]\?+
M/_!.W_DJ/C8#K]A7_P!'M7.^"=4U3]CC]H:Z\/:I)(WA?4V2)YY"=LEJS8AN
M/]]&;:Y]"3Z`;_\`P3N93\3_`!J4=7C:Q!5UZ$?:'P?RP:XU4<ZE.$OB3=SW
M*F`^JX/%U:6M.:C*+\K[?(^BOVU[*2[_`&<_%1B)`B2&9PO=5F5F!]L`UPO_
M``3LO()/A3K5KN5KFWU>0OMZX>-&4D=N#C\*^DO'?A:U\;>#]9T&\7-IJ%K)
M;N/9E(R/SK\Z_@#\0[[]E?XTZEX=\6!X-/G866HN<GRV5OW-V!CF,J6!/;=U
M..=ZS]G7A4>VQY>6_P"W916P5/XTU)+NEN?IKBD9MJ$GI6;8:Y9ZI9QW=I<1
M3V\J"1)4;*.I&00W0C%799PL1)8+]37I]+GQ+C*+Y6M>W4\A_:MU*TTG]G_Q
MM/=+OC:Q:!5`R=SL$'_CQ!S_`(5XQ_P3>T^XA\&>,+EU/D3:A'&C9ZLL0W<=
MN&4_C7"_MN?'JW\>:A:>`?#3G4;6VN%:^EM_G\^Y!VQV\>/O%6)SV)*CL:^J
M?V9?A9+\)OA!HVBW2*FJR@W>H%3D">3EESWV@*F>,[<X&<5YB:JXE271'W%6
M#R_(O8UM)5I)I=4EU\CCOVP_V9H?C[X)BN=+2*+QCI2/)I\S_*)U/WX7/HV!
M@G[IYYY!_)S5].N]%U"YT_4+2>QU"TE:">UN$V2QNIPR%>S#N.PP>003^]IC
M)'WB.,?2OE3]L+]C^T^-6FMXI\-0I8>.;2')XV)J:`?ZJ3TD`R%<\\[22`-O
MT6&K^S=I'XUF^5+$KVU)>\NG<^2/^">WBE_#G[2.G67FA8=9L[FQDST)"^:/
MQW1C\S7M/[04Q^/W[6?AWP)`YFTO2W6"Y4<J,8FNC_W[$:?5B/:OC?X5^))_
MA3\6_#>NZC;3VL^@:I')>6C#9*"C%98V'8XW*??/H<?<W[!'A&Y\4>)?&/Q)
MUA3)>W-R]M$[C)\QV$LY'T+*N?08[5QYI'GJ0BNNI]5P//ZK@L1BY[P]U>K7
MZ'V<+5+335AB4*L:;%`&,`=J_.O]B&\3PW^TIJ>GWJ&&\N+2[LUC89(E242,
MN?95/XU^D3`%2,9'I7YL?M(>%M8_9Y_:,@\=Z-$QT_4+PZO:MNVHTK'_`$B!
MB>`S$NV#_"_LV/+Q2Y)0J+H?9Y!-5HXC"-^]4CIYM:V/TF#CCGCCGL:>>E<%
M\+OBOH7Q<\+VFMZ)<[XI.)K9LB6WDQ\T<BXRK#KSCL>]=WY@&<]J]",E+5'R
M52E4HS=.<6I+=,AN740L21C;GGBOSC_9G`UG]LV^N[63?!]KU>XWH."A<C/T
M)8'/X>]?3O[6/[1%C\)_!5SIFGW"2^+M2@:.TMXV&ZW1LKY[_P!U0?NYQN8`
M#GIY;_P3W^%5QI]OK'CN_CDC2_`L=->48:6%26>5?57;D'N%KSJS56M",?LO
M4^URN,L#E6*Q%9651*,;]7?H8W_!2/3IAJ7@J[`W1&&[@7'(#DQL1^7Z9]*^
MM/@CJT&O?"+P;?6Q7R9M*M2`A&%(B7<OX$%2.Q!KBOVLOA)-\7OA+>6=C%OU
MK3W%_8H/O22*I#1CIRREE],D>E?/?[%'[2%IX1C7X=^*95TZ'[0XTNXF)54<
MO\]N^?NG?G!;&3N7`.,E_98B4GLTA.#S+)(*CK.DW==;/J??-9'B/5UT#0-1
MU)XVE6S@DN#&F-SA5+8&>_%7H[N.4`JP8$9!4YKGOB6V[X?>)%QG.G7`XZ_Z
MMJ]%M\K9\;2A>K&$ENU^9YS^SS^TI9?M!1:R]GHEWI']F-"K_:W#;S(&Z;?3
M;^.>U>G^.<#P;K9YXLY>G7[C5\;_`/!--D$/CDX`)DLB`!@X*2]1]>*^Q_'0
M(\':S@X_T.7MG^`USPDYT>9]4>QCL-#"9C[&DK)-?H?F;^S/^SY=?':7Q"EM
MXFG\.?V;Y))@5F\X2&7`;#KTVGKG.>U>ZG_@GGJL1!/Q,OSSP!`^3_Y$XJC_
M`,$VLI<>/-P*\6).1@<F<CZ]#7W,</UX&.N<URX:A"=--IH^DSO.\;A\;*E"
M?NJW1/HNMCBO@]X"D^%WP\T?PU/J,FK2Z?#Y37LBE6E)).2"3_,US/[6"?\`
M&.OCH@Y`T]_Z5ZRK`@AADCK@\UY1^UB^/V=_'2C_`*!S_P`Q794A:E)+LSY#
M!U)5,=2G+63DG^)YG_P3N/\`Q9;5#ZZW<#_R'%7+_MU?!&:2&W^)OAU'M]3T
M_:NHFV^5]BG*7`]&C/?LN:ZC_@GA%N^"NJ#)_P"0U/R.#_JXJ^FM1TRWU2RG
MM;R&.YMIT,<L4B[E=6&&!!['TK&G353#QB^Q[>,Q\LOSNI76J4G==UU1Y!^S
M+\:X?CC\,[>[G=5UZQ'V74X0-I#@9$@'97&T^QW#J#CY9_8Y./VK?$I'IJ7_
M`*5M5&ZM]2_8K_:17R=[^#]4'RY)VR63-SZ_/"3]2,=-^3=_8OE2Y_:H\12P
MNLL,D>HR(XZ/&UR65AZ\,O';-<+J-U*=.>Z>I])'`PP^%QF)H.]*I"\?*[V^
M1^BX^Y3J:/N4ZO</RT****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"D/2EIK#(H`C/)(]\UXY^U7\/]:^)WP;U30O#UO%<:G</"\<<\HB4
MA9%8_,>G`KV3R\Y&>V*#&&&#R#V-3.*G'E9OAJ\L-5C5AO%W1XC^R1\.M<^%
MOPCCT/Q';PVNI+?7,QCAF$B[&<D<CV/2O;CT],4@C)49;D=QQ3RHP<TH14(J
M*Z!B*TL35E6GO)W9\_?M9_`,_&;P.9M+A#^)](S-8GA?.!XDB)/9AS]0M>7?
ML/\`P7\:_#/QKXCO/%.BR:7;W-A%'$SRHX9Q*6(&WIU[U]G"//).3ZX]J/)"
MGJ.GI7/+#1E557JCUJ6=8JE@)Y>W>$OP6^@':2`03Q7B?[07[,FA?'6Q6>1A
MI/B&U7%KJL*9(_V)!D;TXZ$\=O?V_'/6D`R#DYKHE",URR1Y.&Q-;"5%5HRM
M);'Y]:5\+/VD/V?F:U\*7!U?2`^8X+5TG@(SWADP4)]$(^M3ZWIG[4_QDBFT
MN_MYO#NFR@)*L31V,3`\'+*7D(P>0#CVK[\$0Z]#CKCD4OE\Y.,^N.:XOJBV
MYY6]3Z9<0ROSRH0<_P"9QU_,^8?V>?V,-)^%6I0>(_$,\>M^)DRT/EQE;:T8
MCJBDG+#U.!WQGFOIM1M/;&>P]_\`]=/"$'KQZ4H!'4YKKA2C37+#0^=Q>,K8
MZJZU>5V_N0\@$$'D&HWC^5L8R>Y'7ZU-36&00#@^M:G(?`?[>?[+6I:YXATS
MQUX%\/W6K:A>2?9M4T_3D#,[A2T=QC/!(4HYYSA#P2=WUA^S_P##I/A9\*_#
M_A\QE+J"V$ET6'S&:0EW)]3N8CVQ7HHAPP.[CT%.6(+],YQ3DW*S>Z,J,/81
ME"GI&3NUYV'%<GU&*XSXG_"_0_BOX6N="\06WVBSF^96&!)`X!"R1M_"XSUY
MXR,')SVFW..:&7.1G@]JEI27+(WIU)TYJ<'9K9GY^ZG^R3\7?@CXBGUCX::\
MVH0#HL$@@G:,9*I)&V4E"]L]^@%7+CQE^UAK-NNF?V1+9.?W;7<=G!$[9XY=
MF([]0!ZU]Y>5D8!P/U_6D:W]\'Z9KB^JVTA*R/I_]8*E2TJ]&$Y+JXZOU/A[
MX7_L*:[XC\1#Q#\5]8-ZTLGG3Z=%<--)</QQ+,W5<<;1GCHPK[2TW3+72-/@
ML[6"*UM8$6*.&%`J*B\!0!T`Z`=JT515QV]AP*7;D<$`9[UT4J,::MU/(Q^9
M8G,9)U9:+1);+Y#"NX<Y.1TZ9_PKYA_:&_8LT3XIWEWK>@3PZ!XAN&WW0:/=
M:WS;<9E3LV.-_/!8E2<$?49!QU`_"F&+Y2/YCI5SA&HK,QPF,KX&I[2A*S_!
M^I^>FG>#?VH?@POV#1GO=2L%XC$,\5[!@=`JRG<@]AC\*TKV?]K#XAV\VGSV
M,EA:3Q&*57CMH%=6&""?F('7D8/I7WSY*X.0"3[4HA7;C:OMQTKB^J=.>7WG
MT'^L,F_:2P\.?ORGS;^Q_P#L]:_\#M-UV3Q!=64]SJ;PE(;)F<1!`1AG(&3E
ML\#\Z]Z\564VH^&]3M;=1)--;R1HI(`9BI`&3T^M;.SW.13B,GK77"FH0Y%L
M>!B,95Q6(^LU-97N?G7\/?V=_P!HOX4?;3X5CL-(-]M-P4NK:0OL+;!\R'HK
M-^==H?#_`.UZ%/\`Q-[;I_?LO_C7\J^WA&!V!.<\BG%01C`P:Y5A(I<JG+[S
MVYY_5JOFJ48-_P"'_@GS-\!],^/UGX]9OB/J$%YX:^RR*J*UL2)MR;#^[13T
MW=<UZC^T!X3U/QU\'/%6A:1`DVIWUBT,"22!%+DC@D]/K7H80[NHQ]/\^M*R
M9SC`[CCH:ZHT^6'+>YX];'2GB(XB,(Q:L[)66FIX+^QM\,/$'PF^&=_I'B:V
M@M-0EU*2Z6.&<2@HR(!R.^58?A7O?4D'IBF"%1T)SW[9[U-L&:<(*$5&/0PQ
M6(EBZTJ\_BD[L\8_:9^!L7QM^'5S8Q!$UZR+76FW!&-LH!_=D_W7'RGMG:V#
MM`KYU_8V^!/CSX>_&`ZOXB\/MINGG3I83,9E8"0LO``YP<?I7W<RAO3.,8/2
MHUM]DFX`>O3D]>/UK&>&A.HJG5'I8;.,1AL)4P2UC/3T+(Z4M)T%+74>(%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
F4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
